• 1
    Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008; 68: 9280-9290.
  • 2
    Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011; 128: 347-356.
  • 3
    Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010; 28: 2698-2704.
  • 4
    Burris HA3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011; 29: 398-405.
  • 5
    Hurvitz SA, Dirix L, Kocsis J, et al. Trastuzumab emtansine (T-DM1) versus trastuzumab + docetaxel in previously untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase 2 study (TDM4450g/BO21976) [abstract]. Eur J Cancer. 2011; 47( suppl 1): s330. Abstract 5001.
  • 6
    Helft PR, Schilsky RL, Hoke FJ, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004; 10: 4363-4368.
  • 7
    Milowsky MR, Galsky M, George DJ, et al. Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC) [abstract]. J Clin Oncol. 2006; 24( 18s): 217s. Abstract 4500.
  • 8
    Therasse P, Arbuck SG, Eisenhauser EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205-216.
  • 9
    Lu D, Gupta M, Wang B, et al. An integrated population pharmacokinetic model for a first-in-class HER2 targeted antibody-drug conjugate trastuzumab emtansine (T-DM1): simultaneous modeling of T-DM1 and total trastuzumab pharmacokinetics in heavily pretreated HER2+ metastatic breast cancer patients [abstract]. Clin Pharmacol Ther. 2011; 89( suppl 1): S54. Abstract PII-51.
  • 10
    Bender BC, Schaedeli-Stark F, Joshi A et al. A semi-physiologic population pharmacokinetic/pharmacodynamic (PK/PD) model of thrombocytopenia (TCP) characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive MBC [abstract]. J Clin Oncol. 2011; 29( 15s):71s. Abstract 605.
  • 11
    Mahapatra K, Darbonne W, Bumbaca D, et al. T-DM1-induced thrombocytopenia results from impaired platelet production in a HER2-independent manner [abstract]. Mol Cancer Ther. 2011; 10( 11 suppl). Abstract A135.
  • 12
    Krop IE, Modi S, Elias A, LoRusso P, Choi YJ, Lu M. A dose-escalation study of trastuzumab-DM1 (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive, locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen [abstract]. Cancer Res. 2010; 70( suppl 2): 295s. Abstract P3-14-10.